Ab1676 #ACR22 SAPHYR: Sarilumab in Refractory PMR 52wk SAR 200 mg q2w + 14w taper GC v PBO+GC taper Primary endpt: sustain response at 52w Early term 2/2 COVID, 117 pt SAR remission 28% vs PBO 10%, p=0.02 Data consistent when removes CRP data PBO: more GCs 2/2 PMR flare @Rheumnow https://t.co/kHq3juULX1